Isolated antibody that binds specifically to the differentiation cluster 70 (CD70), bispecific antibody, host cell, use, and method of producing an antibody.
Bispecific antibodies with specific CD70 binding and improved half-life address drug resistance in RCC treatment, enhancing therapeutic efficacy and safety by reducing immune response.
Patent Information
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- PFIZER INC
- Filing Date
- 2019-01-31
- Publication Date
- 2026-07-07
AI Technical Summary
Current treatments for advanced renal cell carcinoma (RCC) face challenges with drug resistance and require continuous infusion due to the short half-life of bispecific antibodies, necessitating the development of antibodies with improved efficacy and safety for treating cancers where CD70 is expressed.
Development of monospecific or bispecific antibodies with specific binding to CD70, featuring longer half-life and reduced Fc interaction, and reduced in vivo release of nonspecific cytokines, utilizing specific CDR sequences for enhanced therapeutic efficacy.
The antibodies provide prolonged therapeutic effect and reduced immune response, offering improved treatment options for CD70-expressing cancers like RCC with enhanced safety and efficacy.